137 related articles for article (PubMed ID: 36708910)
1. The combinational nano-immunotherapy of ferumoxytol and poly(I:C) inhibits melanoma via boosting anti-angiogenic immunity.
Zheng Y; Jiang B; Guo H; Zhang Z; Chen B; Zhang Z; Wu S; Zhao J
Nanomedicine; 2023 Apr; 49():102658. PubMed ID: 36708910
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I : C) promote melanoma regression.
Zhao J; Zhang Z; Xue Y; Wang G; Cheng Y; Pan Y; Zhao S; Hou Y
Theranostics; 2018; 8(22):6307-6321. PubMed ID: 30613299
[TBL] [Abstract][Full Text] [Related]
3. Ferumoxytol-β-glucan Inhibits Melanoma Growth via Interacting with Dectin-1 to Polarize Macrophages into M1 Phenotype.
Liu X; Xu Y; Li Y; Pan Y; Zhao S; Hou Y
Int J Med Sci; 2021; 18(14):3125-3139. PubMed ID: 34400883
[No Abstract] [Full Text] [Related]
4. Immunologically active ferumoxytol-poly(I : C) nanomaterials inhibit metastatic melanoma by regulating myeloid-derived suppressor cell differentiation.
Fang G; Zhang Z; Jiang B; Zheng Y; Xiao X; Wang T; Zhang Z; Zhao J
Biomater Sci; 2023 Jul; 11(15):5337-5346. PubMed ID: 37366334
[TBL] [Abstract][Full Text] [Related]
5. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues.
Zanganeh S; Hutter G; Spitler R; Lenkov O; Mahmoudi M; Shaw A; Pajarinen JS; Nejadnik H; Goodman S; Moseley M; Coussens LM; Daldrup-Link HE
Nat Nanotechnol; 2016 Nov; 11(11):986-994. PubMed ID: 27668795
[TBL] [Abstract][Full Text] [Related]
6. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
[No Abstract] [Full Text] [Related]
7. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Rofstad EK; Halsør EF
Cancer Res; 2000 Sep; 60(17):4932-8. PubMed ID: 10987309
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical properties of ferumoxytol, a new intravenous iron preparation.
Balakrishnan VS; Rao M; Kausz AT; Brenner L; Pereira BJ; Frigo TB; Lewis JM
Eur J Clin Invest; 2009 Jun; 39(6):489-96. PubMed ID: 19397688
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging of stem cell-macrophage interactions with ferumoxytol and ferumoxytol-derived nanoparticles.
Nejadnik H; Tseng J; Daldrup-Link H
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jul; 11(4):e1552. PubMed ID: 30734542
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo.
Westphal JR; Van't Hullenaar R; Peek R; Willems RW; Crickard K; Crickard U; Askaa J; Clemmensen I; Ruiter DJ; De Waal RM
Int J Cancer; 2000 Jun; 86(6):768-76. PubMed ID: 10842189
[TBL] [Abstract][Full Text] [Related]
11. Effects of Cyclooxygenase-2 in Canine Melanoma-derived Extracellular Vesicles on Tumor Microenvironment
Kim NH; An JH; Lee JH; Park SM; Kim KB; Kim TH; Oh YI; Seo KW; Youn HY
Anticancer Res; 2022 Nov; 42(11):5397-5405. PubMed ID: 36288867
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis.
Huang S; Xie K; Bucana CD; Ullrich SE; Bar-Eli M
Clin Cancer Res; 1996 Dec; 2(12):1969-79. PubMed ID: 9816156
[TBL] [Abstract][Full Text] [Related]
13. Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy.
Li Q; Su R; Bao X; Cao K; Du Y; Wang N; Wang J; Xing F; Yan F; Huang K; Feng S
Acta Biomater; 2022 May; 144():109-120. PubMed ID: 35314366
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic VEGF
Ganta VC; Choi M; Farber CR; Annex BH
Circulation; 2019 Jan; 139(2):226-242. PubMed ID: 30586702
[TBL] [Abstract][Full Text] [Related]
15. Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.
Huang Y; Hsu JC; Koo H; Cormode DP
Theranostics; 2022; 12(2):796-816. PubMed ID: 34976214
[TBL] [Abstract][Full Text] [Related]
16. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.
Kowalczyk M; Banach M; Rysz J
J Nephrol; 2011; 24(6):717-22. PubMed ID: 21956770
[TBL] [Abstract][Full Text] [Related]
17. Translatable Drug-Loaded Iron Oxide Nanophore Sensitizes Murine Melanoma Tumors to Monoclonal Antibody Immunotherapy.
Stater EP; Morcos G; Isaac E; Ogirala A; Hsu HT; Longo VA; Grimm J
ACS Nano; 2023 Apr; 17(7):6178-6192. PubMed ID: 36971591
[TBL] [Abstract][Full Text] [Related]
18. The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition.
Daum S; Hagen H; Naismith E; Wolf D; Pircher A
Front Cell Dev Biol; 2020; 8():610903. PubMed ID: 33469537
[TBL] [Abstract][Full Text] [Related]
19. Melanoma exosome induction of endothelial cell GM-CSF in pre-metastatic lymph nodes may result in different M1 and M2 macrophage mediated angiogenic processes.
Hood JL
Med Hypotheses; 2016 Sep; 94():118-22. PubMed ID: 27515216
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of tumor and endothelial cells by gonadotropin-releasing hormone agonists to reduce melanoma angiogenesis.
Moretti RM; Mai S; Montagnani Marelli M; Bani MR; Ghilardi C; Giavazzi R; Taylor DM; Martini PG; Limonta P
Endocrinology; 2010 Oct; 151(10):4643-53. PubMed ID: 20685877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
